NO20034345D0 - Pyridazinon aldose reduktase inhibitorer - Google Patents
Pyridazinon aldose reduktase inhibitorerInfo
- Publication number
- NO20034345D0 NO20034345D0 NO20034345A NO20034345A NO20034345D0 NO 20034345 D0 NO20034345 D0 NO 20034345D0 NO 20034345 A NO20034345 A NO 20034345A NO 20034345 A NO20034345 A NO 20034345A NO 20034345 D0 NO20034345 D0 NO 20034345D0
- Authority
- NO
- Norway
- Prior art keywords
- reductase inhibitors
- aldose reductase
- pyridazinone aldose
- pyridazinone
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28005101P | 2001-03-30 | 2001-03-30 | |
| PCT/IB2002/000320 WO2002079198A1 (fr) | 2001-03-30 | 2002-01-31 | Inhibiteurs pyridazinone d'aldose réductase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034345D0 true NO20034345D0 (no) | 2003-09-29 |
| NO20034345L NO20034345L (no) | 2003-09-29 |
Family
ID=23071435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034345A NO20034345L (no) | 2001-03-30 | 2003-09-29 | Pyridazinon aldose reduktase inhibitorer |
Country Status (44)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0934061T6 (en) | 1996-07-24 | 2015-01-26 | Warner Lambert Co | Isobutylgaba and its derivatives for the treatment of pain |
| ATE297902T1 (de) * | 2001-02-28 | 2005-07-15 | Pfizer Prod Inc | Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren |
| WO2002079198A1 (fr) * | 2001-03-30 | 2002-10-10 | Pfizer Products Inc. | Inhibiteurs pyridazinone d'aldose réductase |
| AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| TWI250980B (en) * | 2002-01-09 | 2006-03-11 | Pfizer Prod Inc | Process and intermediates for pyridazinone antidiabetic agents |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| CA2568640C (fr) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Composition pharmaceutique contenant de l'irbesartan |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP1769088A2 (fr) * | 2004-06-30 | 2007-04-04 | Whitehead Institute For Biomedical Research | Procedes pour analyse de site haut rendement au niveau du genome |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| CA2636007A1 (fr) * | 2006-01-13 | 2007-07-26 | Wyeth | 1h-indoles substitues par un groupe sulfonyle en tant que ligands pour les recepteurs de la 5-hydroxytryptamine |
| EP2041123B9 (fr) | 2006-06-27 | 2013-01-02 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés |
| EP2094643B1 (fr) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | Inhibiteurs d'amino cetp étendus |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| AU2010328186B2 (en) | 2009-12-08 | 2014-12-18 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| KR20140091522A (ko) * | 2011-09-15 | 2014-07-21 | 타이페이 메디컬 유니이버시티 | 심부전증 또는 신경 손상을 치료하기 위한 인돌릴 및 인돌리닐 하이드록사메이트의 용도 |
| US9339542B2 (en) * | 2013-04-16 | 2016-05-17 | John L Couvaras | Hypertension reducing composition |
| EP2986599A1 (fr) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| WO2016055901A1 (fr) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Composés d'amide substitué |
| EP3283074A4 (fr) * | 2015-04-14 | 2018-12-05 | Case Western Reserve University | Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte |
| WO2017168174A1 (fr) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | Nouvelles formes pharmaceutiques du sildénafil |
| BR112018076244A2 (pt) | 2016-06-21 | 2019-03-26 | The Trustees Of Columbia University In The City Of New York | inibidores da aldose redutase e métodos de uso destes |
| WO2018002673A1 (fr) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii |
| WO2018058109A1 (fr) * | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions et méthodes pour le traitement de troubles métaboliques |
| EP3548035A4 (fr) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| SG11202000730QA (en) | 2017-07-28 | 2020-02-27 | Applied Therapeutics Inc | Compositions and methods for treating galactosemia |
| CA3125765A1 (fr) | 2019-01-18 | 2020-07-23 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procedes d'utilisation |
| WO2020243423A1 (fr) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| WO2022120353A1 (fr) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| WO1992009594A1 (fr) * | 1990-11-30 | 1992-06-11 | Tsumura & Co. | Derive de benzopyrone et inhibiteur de reductase d'aldose contenant ce derive en tant qu'ingredient actif |
| CA2107104A1 (fr) | 1991-03-28 | 1992-09-29 | Banavara L. Mylari | Acides pyridazinoneacetiques utilises comme inhibiteurs de l'aldose reductase |
| US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| HUP0003647A3 (en) * | 1997-09-24 | 2002-12-28 | Orion Corp | Bisethers of 1-oxa, aza and thianaphthalen-2-ones, their use for producing medicaments, the medicaments and their intermediates |
| FR2822827B1 (fr) * | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| WO2002079198A1 (fr) * | 2001-03-30 | 2002-10-10 | Pfizer Products Inc. | Inhibiteurs pyridazinone d'aldose réductase |
| IL157935A0 (en) * | 2001-04-30 | 2004-03-28 | Pfizer Prod Inc | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| TWI250980B (en) * | 2002-01-09 | 2006-03-11 | Pfizer Prod Inc | Process and intermediates for pyridazinone antidiabetic agents |
-
2002
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/fr active IP Right Grant
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 EP EP04023149A patent/EP1491540B1/fr not_active Expired - Lifetime
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 EP EP02716247A patent/EP1373259B1/fr not_active Expired - Lifetime
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 EP EP04023150A patent/EP1491541B1/fr not_active Expired - Lifetime
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active IP Right Cessation
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/fr not_active Abandoned
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
-
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
-
2004
- 2004-06-24 HK HK04104538A patent/HK1061678A1/xx not_active IP Right Cessation
-
2006
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60217930D1 (de) | Pyridazinon Aldose Reductase Inhibitoren | |
| CY2015028I1 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
| DE60234125D1 (de) | E inhibitoren | |
| ATE397925T1 (de) | Cis-imidazoline als mdm2-hemmer | |
| PT1370553E (pt) | Inibidores de rhoquinase | |
| DE60218138D1 (de) | Rho-kinase inhibitoren | |
| DE60301683D1 (de) | Leseverstärker | |
| ATE368651T1 (de) | Pyridazinon-derivate als gsk-3beta-hemmer | |
| IS7243A (is) | C-5 breytt indazólýlpýrrólótríazín | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| ATE484496T1 (de) | Metalloproteinaseinhibitoren | |
| NO20042742L (no) | Pyrimidinforbindelser | |
| EE200300450A (et) | Metalloproteinaasi inhibiitorid | |
| DE60239456D1 (de) | Amplifizierungsverfahren | |
| DE60201856D1 (de) | Klasse-D Verstärker | |
| DE60222443D1 (de) | Vorverstärkungsschaltung | |
| ATA6972001A (de) | Sonnenuhr | |
| SE0100694D0 (sv) | DHFR inhibitors | |
| ITVA20020070A1 (it) | Composizioni farmaceutico-dietetiche comprendenti inibitori della hmg-coa reduttasi e/o polielettroliti. | |
| ATE270267T1 (de) | Scyphostatin-analoga als smase-inhibitoren | |
| UA5096S (uk) | Суцільнометалевий піввагон | |
| FI20010995A (fi) | Audiovahvistin | |
| FI20011758A0 (fi) | Henkilökohtainen virtsauslaite |